REGN - Spark Newswire

3 minute read

Regeneron Reports FDA Expands Approval Of Dupixent To Include Children 6-11 Years With Moderate-To-Severe Asthma

Today, 4:02 PM

Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option Only biologic medicine approved for children

REGN

2 minute read

Esperion Chops 40% Workforce As Launch Of Cholesterol Medication Falters

By Vandana Singh

Today, 4:02 PM

Esperion Therapeutics Inc's (NASDAQ: ESPR) cholesterol drug marketing strategy has soured badly, as it has been struggling to sell its heart disease pill for more than a year.

AMGN

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Friday, Oct. 15, 2021: SE, SMFR, NSTG, REGN

By Benzinga Newsdesk

Today, 4:02 PM

Sea (SE) - 194 Sema4 Holdings (SMFR) - 628 NanoString Technologies (NSTG) - 153,997 Regeneron Pharmaceuticals (REGN) - 13,078

NSTG

1 minute read

FDA
News

Why Regeneron Shares Are Rising Today

By Adam Eckert

Today, 4:02 PM

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is trading higher Thursday after the company announced the FDA accepted for priority review a Biologics License Application for REGEN-COV to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals.

REGN

2 minute read

FDA
News

Regeneron Pharmaceuticals Announces FDA Accepts REGEN-COV For Priority Review For Treatment And Prophylaxis Of COVID-19

By Benzinga Newsdesk

Today, 4:02 PM

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for

REGN

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Monday, Oct. 11, 2021: SHOP, SE, NSTG, PRLB, IRDM, COIN, NXPI, LC, SMFR, TAK, VEEV, SDGR, EDIT, VRTX, REGN, OPEN

By Benzinga Newsdesk

Today, 4:02 PM

Shopify (SHOP) - 860 Sea (SE) - 5,757 NanoString Technologies (NSTG) - 160,139 Proto Labs (PRLB) - 152,226 Iridium Communications (IRDM)

COIN

1 minute read

Analyst Ratings

Expert Ratings For Regeneron Pharmaceuticals

By Benzinga Insights

Today, 4:02 PM

Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings:

REGN

1 minute read

Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to $571

By Benzinga Newsdesk

Today, 4:02 PM

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and lowers the price target from $606 to $571.

REGN